Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
暂无分享,去创建一个
T. Jefferson | C. Del Mar | P. Doshi | L. Dooley | R. Foxlee | Mark A Jones | Mark Jones
[1] Robert Schechter,et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. Coleman. Antivirals for Treatment of Influenza: A Systematic Review and Meta-Analysis of Observational Studies , 2012 .
[3] Yonghong Xiao,et al. Antiviral Therapy and Outcomes of Patients with Pneumonia Caused by Influenza A Pandemic (H1N1) Virus , 2012, PloS one.
[4] D. Fleming,et al. Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza , 2000, PharmacoEconomics.
[5] A. Monto,et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. , 2011, The Journal of infectious diseases.
[6] Takao Takahashi,et al. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. , 2011, The Journal of infection.
[7] J. Pachón,et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. , 2011, Chest.
[8] M. Hernán,et al. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. R. Pérez Padilla,et al. Reducing Occurrence and Severity of Pneumonia Due to Pandemic H1N1 2009 by Early Oseltamivir Administration: A Retrospective Study in Mexico , 2011, PloS one.
[10] H. Hemilä. Zinc Lozenges May Shorten the Duration of Colds: A Systematic Review , 2011, The open respiratory medicine journal.
[11] Michael M. Peng,et al. Safety profile of oseltamivir during the 2009 influenza pandemic , 2011, Pharmacoepidemiology and drug safety.
[12] Jessica E. Jones,et al. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung , 2011, Influenza and other respiratory viruses.
[13] Weizhong Yang,et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Matthew Biggerstaff,et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Mark Jones,et al. Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. , 2011, The International journal of risk & safety in medicine.
[16] M. Krause,et al. ["Oseltamivir-induced delirium"]. , 2010, Therapeutische Umschau. Revue therapeutique.
[17] Y. Joung,et al. Oseltamivir (Tamiflu) Induced Depressive Episode in a Female Adolescent , 2010, Psychiatry investigation.
[18] F. Tubach,et al. Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial , 2010, PLoS medicine.
[19] D. Luton,et al. French Experience of 2009 A/H1N1v Influenza in Pregnant Women , 2010, PloS one.
[20] H. Kido,et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. , 2010, Microbes and infection.
[21] Benjamin J Cowling,et al. Comparative epidemiology of pandemic and seasonal influenza A in households. , 2010, The New England journal of medicine.
[22] H. Tamai,et al. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection , 2010, Brain and Development.
[23] W. Callaghan,et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. , 2010, JAMA.
[24] Samson S. Y. Wong,et al. The Natural Viral Load Profile of Patients With Pandemic 2009 Influenza A(H1N1) and the Effect of Oseltamivir Treatment , 2010, Chest.
[25] Y. Leo,et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] O. Ramilo,et al. Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age , 2010, The Pediatric infectious disease journal.
[27] E. Okamoto. Is oseltamivir (Tamiflu®) safe? Re-examining the Tamiflu ‘ado’ from Japan , 2010, Expert review of pharmacoeconomics & outcomes research.
[28] H. Kelly,et al. A pandemic response to a disease of predominantly seasonal intensity , 2010, The Medical journal of Australia.
[29] H. Osaka,et al. A Pharmacoepidemiologic Study on the Relationship between Neuropsychiatric Symptoms and Therapeutic Drugs after Influenza Infection , 2010 .
[30] Bin Cao,et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. , 2009, The New England journal of medicine.
[31] Peter Doshi,et al. Neuraminidase inhibitors—the story behind the Cochrane review , 2009, BMJ : British Medical Journal.
[32] Tom Jefferson,et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis , 2009, BMJ : British Medical Journal.
[33] C. Mar,et al. Possible harms of oseltamivir—a call for urgent action , 2009, The Lancet.
[34] D. Bravata,et al. Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza , 2009, Annals of Internal Medicine.
[35] Christian Stock,et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.
[36] C. Chiu,et al. INFLUENZA-ASSOCIATED CENTRAL NERVOUS SYSTEM DYSFUNCTION IN TAIWANESE CHILDREN: CLINICAL CHARACTERISTICS AND OUTCOMES WITH AND WITHOUT ADMINISTRATION OF OSELTAMIVIR , 2009, The Pediatric infectious disease journal.
[37] T. Jefferson,et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review , 2007, BMJ : British Medical Journal.
[38] Frederick Hayden,et al. Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] A. Taket,et al. How far does screening women for domestic (partner) violence in different health-care settings meet criteria for a screening programme? Systematic reviews of nine UK National Screening Committee criteria. , 2009, Health technology assessment.
[40] T. Jefferson,et al. Cochrane Review: Interventions for the interruption or reduction of the spread of respiratory viruses , 2008, Evidence-based child health : a Cochrane review journal.
[41] M. Madjid,et al. The Influence of Oseltamivir Treatment on the Risk of Stroke after Influenza Infection , 2008, Cardiology.
[42] D. Altman,et al. Assessing Risk of Bias in Included Studies , 2008 .
[43] M. Tanabe,et al. Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice. , 2008, Biological & pharmaceutical bulletin.
[44] R. Saito,et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. , 2008, The Tohoku journal of experimental medicine.
[45] R. Hama. Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships , 2008 .
[46] R. Gieschke,et al. Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir , 2008, Drug safety.
[47] S. Kashiwagi,et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. , 2008, The Journal of infection.
[48] W. A. Blumentals,et al. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. , 2007, MedGenMed : Medscape general medicine.
[49] S. Kashiwagi,et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. , 2007, The Journal of infection.
[50] F. Henderson,et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. , 2007, Clinical therapeutics.
[51] S. Kashiwagi,et al. Zanamivir treatment is equally effective for both influenza A and influenza B. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] B. Skipper,et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. , 2007, Chest.
[53] Ichiko Fuyuno,et al. Tamiflu side effects come under scrutiny , 2007, Nature.
[54] R. Peebles,et al. Cutting Edge: Oseltamivir Decreases T Cell GM1 Expression and Inhibits Clearance of Respiratory Syncytial Virus: Potential Role of Endogenous Sialidase in Antiviral Immunity1 , 2007, The Journal of Immunology.
[55] M. Kiso,et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] H. Hemilä,et al. Vitamin C for preventing and treating pneumonia. , 2007, The Cochrane database of systematic reviews.
[57] S. Kashiwagi,et al. A change in the effectiveness of amantadine for the treatment of influenza over the 2003–2004, 2004–2005, and 2005–2006 influenza seasons in Japan , 2007, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[58] N. Maeda,et al. Vitamin C deficiency increases the lung pathology of influenza virus-infected gulo-/- mice. , 2006, The Journal of nutrition.
[59] S. Kashiwagi,et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[60] A. Monto. Antivirals for influenza in healthy adults , 2006, The Lancet.
[61] S. Golder,et al. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. , 2006, Health information and libraries journal.
[62] Ji-hong Zhu,et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population* , 2006, Current medical research and opinion.
[63] R. Bettis,et al. Impact of Influenza Treatment with Oseltamivir on Health, Sleep and Daily Activities of Otherwise Healthy Adults and Adolescents , 2006, Clinical drug investigation.
[64] Yi Guan,et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.
[65] S. Gravenstein,et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. , 2005, Journal of the American Medical Directors Association.
[66] F. Hayden,et al. Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment , 2005, Antiviral therapy.
[67] W. Lim,et al. Bird flu and pandemic flu , 2005, BMJ : British Medical Journal.
[68] M. Hosoya,et al. VIRAL SHEDDING IN CHILDREN WITH INFLUENZA VIRUS INFECTIONS TREATED WITH NEURAMINIDASE INHIBITORS , 2005, The Pediatric infectious disease journal.
[69] Angus Nicoll,et al. Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.
[70] Harri Hemilä,et al. Vitamin C for Preventing and Treating the Common Cold , 2005, PLoS medicine.
[71] S. Kashiwagi,et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] Martin Hirst,et al. Human Illness from Avian Influenza H7N3, British Columbia , 2004, Emerging infectious diseases.
[73] Yoshihiro Kawaoka,et al. oseltamivir: descriptive study , 2022 .
[74] A. Osterhaus,et al. For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .
[75] P. Ward,et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. , 2004, The Journal of infectious diseases.
[76] P. Ward,et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. , 2003, Archives of internal medicine.
[77] A. Sutton,et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials , 2003, BMJ : British Medical Journal.
[78] D Gillatt,et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. , 2003, Health technology assessment.
[79] T. Puhakka,et al. Zanamivir: a Significant Reduction in Viral Load During Treatment in Military Conscripts with Influenza , 2003, Scandinavian journal of infectious diseases.
[80] F. Hayden,et al. Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza , 2002, Antiviral therapy.
[81] Yuan-jue Zhu,et al. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. , 2003, Chinese medical journal.
[82] F Y Aoki,et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. , 2003, The Journal of antimicrobial chemotherapy.
[83] A. Sheikh,et al. Neuraminidase inhibitors for preventing and treating influenza in children. , 2003, The Cochrane database of systematic reviews.
[84] A. Monto,et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. , 2002, The Journal of infectious diseases.
[85] P Barton,et al. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. , 2002, Health technology assessment.
[86] R. Milne,et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. , 2002, Health technology assessment.
[87] Malbea A Lapete,et al. Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .
[88] J. Oxford,et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.
[89] S. Kudoh,et al. [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial]. , 2000, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.
[90] S. Kudoh,et al. [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial]. , 2000, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.
[91] F. Hayden,et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. , 2000, Archives of internal medicine.
[92] A. Monto,et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. , 2000, The New England journal of medicine.
[93] K. Murphy,et al. Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease , 2000 .
[94] P. Ward,et al. The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro 64–0796/GS4104) in Healthy Adult and Elderly Volunteers , 2000, Journal of clinical pharmacology.
[95] D. Stein,et al. Direct Measurement of the Anti-Influenza Agent Zanamivir in the Respiratory Tract following Inhalation , 2000, Antimicrobial Agents and Chemotherapy.
[96] S. Trottier,et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.
[97] S. Trottier,et al. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. , 2000, The Journal of infectious diseases.
[98] F. Hayden,et al. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[99] John J. Treanor,et al. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .
[100] T. Jefferson,et al. Prevention and early treatment of influenza in healthy adults. , 2000, Vaccine.
[101] H. Jackson,et al. Oral Oseltamivir in Human Experimental Influenza B Infection , 1999, Antiviral therapy.
[102] M. Mäkelä,et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. , 2000, The Journal of infection.
[103] ohnson,et al. USE OF THE SELECTIVE ORAL NEURAMINIDASE INHIBITOR OSELTAMIVIR TO PREVENT INFLUENZA , 2000 .
[104] A. Monto,et al. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. , 1999, The Journal of antimicrobial chemotherapy.
[105] P. Ward,et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.
[106] A. Monto,et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. , 1999, The Journal of infectious diseases.
[107] A. Monto,et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. , 1999, JAMA.
[108] F. Hayden,et al. Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection , 1999, Antimicrobial Agents and Chemotherapy.
[109] S. Kudoh,et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. , 1999, Antiviral therapy.
[110] Alan Bye,et al. Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers , 1999, Clinical pharmacokinetics.
[111] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[112] T. Jefferson. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. , 1998, Vaccine.
[113] R. Belshe. Influenza as a zoonosis: how likely is a pandemic? , 1998, The Lancet.
[114] M. Peiris,et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus , 1998, The Lancet.
[115] R. Webster,et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.
[116] F. Hayden,et al. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. , 1997, The Journal of infectious diseases.
[117] R. Couch. A new antiviral agent for influenza--is there a clinical niche? , 1997, The New England journal of medicine.
[118] Leming,et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .
[119] D. Bonn. Spared an influenza pandemic for another year? , 1997, The Lancet.
[120] The quest for trials on the efficacy of human vaccines. Results of the handsearch of Vaccine. , 1996, Vaccine.
[121] F. Hayden,et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.
[122] D. Sackett,et al. Cochrane Collaboration , 1994, BMJ.
[123] D. H. Watts,et al. Antiviral agents. , 1992, Obstetrics and gynecology clinics of North America.
[124] R. Stocker,et al. Oxidative stress in lungs of mice infected with influenza A virus. , 1992, Free radical research communications.
[125] M. Thobaben,et al. Prevention and Control of Influenza , 2003, MMWR. Morbidity and mortality weekly report.
[126] R. Douglas,et al. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine , 1983, Antimicrobial Agents and Chemotherapy.
[127] J. A. Kimbarowski,et al. [Colored precipitation reaction of the urine according to Kimbarowski (FARK) as an index of the effect of ascorbic acid during treatment of viral influenza]. , 1967, Das Deutsche Gesundheitswesen.